Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
暂无分享,去创建一个
Ivan Rusyn | Fred A Wright | Oksana Sirenko | Carole Crittenden | Jessica A. Wignall | I. Rusyn | F. Wright | O. Sirenko | Evan F Cromwell | Jessica A Wignall | E. Cromwell | C. Crittenden
[1] Arthur Christopoulos,et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.
[2] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[3] Ivan Rusyn,et al. Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells , 2013, Journal of biomolecular screening.
[4] Clay W Scott,et al. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. , 2013, Toxicology letters.
[5] B. Fermini,et al. Comparative gene expression profiling in human-induced pluripotent stem cell--derived cardiocytes and human and cynomolgus heart tissue. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[6] James A Thomson,et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.
[7] Donald M Bers,et al. Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.
[8] Fabio Cerignoli,et al. High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. , 2012, Journal of pharmacological and toxicological methods.
[9] E. Matthews,et al. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities. , 2010, Regulatory toxicology and pharmacology : RTP.
[10] W Suter,et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? , 2011, British journal of pharmacology.
[11] Ivan Rusyn,et al. Predictive modeling of chemical hazard by integrating numerical descriptors of chemical structures and short-term toxicity assay data. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[12] D. Bers. Cardiac excitation–contraction coupling , 2002, Nature.
[13] P. Alvarez,et al. QT alterations in psychopharmacology: proven candidates and suspects. , 2010, Current drug safety.
[14] Salomon Sand,et al. The point of transition on the dose‐effect curve as a reference point in the evaluation of in vitro toxicity data , 2012, Journal of applied toxicology : JAT.
[15] Flemming Steen Jørgensen,et al. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. , 2011, Combinatorial chemistry & high throughput screening.
[16] Amy Pointon,et al. Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[17] Yvonne Will,et al. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[18] Erik Willems,et al. Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery , 2013, Circulation research.
[19] K. Mubagwa,et al. Insights into the effects of diclofenac and other non‐steroidal anti‐inflammatory agents on ion channels , 2012, The Journal of pharmacy and pharmacology.
[20] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[21] N. Decher,et al. Kvβ1.3 Reduces the Degree of Stereoselective Bupivacaine Block of Kv1.5 Channels , 2007, Anesthesiology.
[22] K L Kolaja,et al. Opportunities for Use of Human iPS Cells in Predictive Toxicology , 2011, Clinical pharmacology and therapeutics.
[23] P P Humphrey,et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. , 1994, Pharmacological reviews.
[24] Liang Guo,et al. Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.
[25] Fred A. Wright,et al. ToxPi GUI: an interactive visualization tool for transparent integration of data from diverse sources of evidence , 2013, Bioinform..
[26] J. Valentin,et al. In vitro models of proarrhythmia , 2008, British journal of pharmacology.
[27] P. Williams. The role of pharmacological profiling in safety assessment. , 1990, Regulatory toxicology and pharmacology : RTP.
[28] Liang Guo,et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[29] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..